

**TAVR AND PACEMAKER IMPLANTATION**

Abstract nos: 555 - 559

**TCT-555**

**Post-Balloon Dilatation Following TAVR Implantation Increases Pacemaker Dependency**



Rachel Kaplan,<sup>1</sup> Ajay Yadlapati,<sup>2</sup> Rod Passman,<sup>2</sup> Bradley Knight,<sup>2</sup> Ranya Sweis,<sup>3</sup> Mark Ricciardi,<sup>1</sup> Duc Thinh Pham,<sup>1</sup> S. Malaisrie,<sup>4</sup> Charles Davidson,<sup>1</sup> James Flaherty<sup>2</sup>

<sup>1</sup>Northwestern University, Chicago, Illinois, United States; <sup>2</sup>Northwestern, Chicago, Illinois, United States; <sup>3</sup>Northwestern University, Feinberg School of Medicine, Chicago, Illinois, United States; <sup>4</sup>Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States

**BACKGROUND** Transcatheter aortic valve replacement (TAVR) is increasingly used to treat severe aortic stenosis. A frequent complication of TAVR is atrioventricular (AV) block requiring a permanent pacemaker (PPM). The long-term dependency of pacing after TAVR is unknown. Post-balloon dilatation (PBD) immediately after implantation is frequently done. Its long-term influence on AV block is unknown.

**METHODS** Of 409 consecutive patients without prior PPM, undergoing TAVR (77% balloon-expandable, 23% self-expandable valve), 48 (11.7%) received a new PPM. Patients receiving a late PPM (>10 days after TAVR, n=5), a biventricular device (n=3), or who died within 30 days (n=1) were excluded. PPM dependency was defined as AV block with a ventricular escape rate ≤ 40 bpm. Patient and procedural characteristics were examined according to PPM dependency status.

**RESULTS** Nineteen of the 39 patients (48.8%) in the study group who received a PPM following TAVR were dependent at 30-days. There was no significant difference in age (80.1 ± 9.3 vs. 82.8 ± 6.7) or gender (47.4% and 55.0% female) between dependent and non-dependent groups. PPM dependency was more common after a self-expanding valve (47.4% vs. 15.0%, p = 0.03). PBD was performed in 25% of all TAVRs. Among patients without a pre-existing PPM, PBD was associated with a higher rate of new PPM (17.5% vs. 9.8%, p=0.04). Patients who underwent PBD also had a higher rate of PPM dependency (73.7% vs. 20.0%, p < 0.01). PPM dependent patients received the device earlier in the hospitalization (1 ± 1.6 days vs. 4 ± 2.6 days post-TAVR, p < 0.01) (Table 1).

Variable	Non-dependent (N = 20)	Dependent (N = 19)	P value
Median Valve Size (mm)	26	26	
Balloon expandable Valve Type	17 (85.0%)	10 (52.6%)	0.03
Self-expanding Valve Type	3 (15.0%)	9 (47.4%)	0.03
Pre-op PR (msec)	183.7 ± 41.9*	176.9 ± 26.6'	0.55
Pre-op QRS (msec)	111.1 ± 36.5	119.3 ± 25.3	0.42
Days post-TAVR when PPM was placed	4 ± 2.6	1 ± 1.6	< 0.01
Post-balloon dilatation by valve type (%)			
- Balloon expandable	23.5	90.0	< 0.01
- Self-expanding	0	55.6	0.10

**CONCLUSION** Half of patients who receive a new PPM following TAVR are not clearly pacemaker dependent at follow-up. PBD is associated with a markedly increased risk of PPM dependency.

**CATEGORIES STRUCTURAL:** Electrophysiology

**TCT-556**

**Exposure to Glucocorticoids Prior to Transcatheter Aortic Valve Replacement is Associated with Reduced Incidence of High-Degree AV block and Pacemaker**



Brett Oestreich,<sup>1</sup> Selcuk Adabag,<sup>2</sup> Rosemary Kelly,<sup>3</sup> Gregory Helmer,<sup>4</sup> Ganesh Raveendran,<sup>5</sup> Demetris Yannopoulos,<sup>1</sup> Timinder Biring,<sup>6</sup> Santiago Garcia<sup>1</sup>

<sup>1</sup>University of Minnesota, Minneapolis, Minnesota, United States; <sup>2</sup>University of Minnesota and Minneapolis VA; <sup>3</sup>University of Minnesota; <sup>4</sup>University of Minnesota, Excelsior, Minnesota, United States; <sup>5</sup>University of Minnesota, Saint Paul, Minnesota, United States; <sup>6</sup>UMP, Woodbury, Minnesota, United States

**BACKGROUND** A significant proportion of patients that receive a permanent pacemaker (PPM) after TAVR is not pacemaker-dependent during follow-up. Tissue edema and inflammation, which occur at the device landing zone during valve deployment, may contribute to the pathophysiology of conduction block. As such, glucocorticoids may have therapeutic effects due to their anti-edema and anti-inflammatory properties.

**METHODS** We hypothesized that exposure to glucocorticoids prior to TAVR will reduce the incidence of conduction abnormalities requiring PPM implantation after TAVR. We included 167 consecutive patients treated with TAVR at the Minneapolis VA Medical Center and University of Minnesota. Exposure to glucocorticoids was assessed by linking electronic medical and pharmacy records. The primary outcome was a new PPM within 30-days of the index TAVR procedure. Patients with pre-existing left bundle branch block or PPM were excluded.

**RESULTS** Of the 167patients included, 16 (9.5%) were exposed to glucocorticoids prior to TAVR.No differences in age, STS score, pre-existing right bundle branch block or valve type were seen among patients exposed to glucocorticoids versus those who were unexposed (table). Patients exposed to glucocorticoids were more likely to have moderate/severe COPD (43% versus 18%, p<0.01). The cumulative incidence of PPM implantation at 30-days after TAVR was 18%. None of the patients exposed to glucocorticoids required a PPM while 30 (19%) of the unexposed patients did (p=0.04).

	Steroids (n=16)	No Steroids (n=151)	P value
Age	76 (10)	80 (9)	0.07
STS median (IQR)	5.8 (3.9-7.9)	5.6 (3.1-8.8)	0.80
COPD (mod/severe)	(7) 43%	(28) 18%	<0.01
Right bundle brunch block	(1) 7%	21 (13%)	0.49
Implantation Depth (mm, IQR)	4 (3.1-4.5)	4.4 (3.5-5.8)	0.28
Sapien XT	7 (43%)	54 (36%)	0.58
Sapien 3	8 (50%)	79 (52%)	0.87
Corevalve/Evolut	1 (7%)	17 (12%)	0.55
New Pacemaker	0 (0%)	30 (19%)	0.04

**CONCLUSION** Exposure to glucocorticoids prior to TAVR is associated with reduced incidence of PPM requirement. Tissue edema and inflammation may be significant contributors to the pathophysiology of conduction abnormalities after TAVR and could represent a therapeutic target.

**CATEGORIES STRUCTURAL:** Valvular Disease: Aortic

**TCT-557**

**Predictors of advanced conduction disturbances requiring a late (>48 hours) permanent pacemaker following transcatheter aortic valve implantation**



Antonio Mangieri,<sup>1</sup> Giuseppe Lanzillo,<sup>2</sup> Letizia Bertoldi,<sup>3</sup> Richard Jabbour,<sup>4</sup> Damiano Regazzoli,<sup>1</sup> Marco Ancona,<sup>1</sup> Akihito Tanaka,<sup>1</sup> Satoru Mitomo,<sup>5</sup> Claudio Montalto,<sup>6</sup> Matteo Pagnesi,<sup>6</sup> Francesco Giannini,<sup>1</sup> Matteo Montorfano,<sup>6</sup> Alaide Chieffo,<sup>1</sup> Josep Rodés-Cabau,<sup>7</sup> Ottavio Alfieri,<sup>8</sup> Antonio Colombo,<sup>9</sup> Azeem Latib<sup>1</sup>  
<sup>1</sup>Interventional Cardiology Institute San Raffaele Hospital, Milan, Milan, Italy; <sup>2</sup>San Raffaele Scientific Institute, Milan, Italy., Milano, Milan, Italy; <sup>3</sup>San Raffaele Scientific Institute, Milano, Milan, Italy; <sup>4</sup>Imperial College London, London, United Kingdom; <sup>5</sup>IRCCS San Raffaele Scientific Institute, Milan, Milan, Italy; <sup>6</sup>San Raffaele Scientific Institute, Milan, Milan, Italy; <sup>7</sup>Quebec Heart and Lung Institute/Laval University, Quebec, Quebec, Canada; <sup>8</sup>San Raffaele Hospital, Milan, Milan, Italy; <sup>9</sup>Interventional Cardiology Institute San Raffaele Hospital - Stamford Hospital - Columbia University - Centro Cuore Columbus, Milan, Milan, Italy

**BACKGROUND** To analyse and determine the predictors of advanced conduction disturbances requiring late (> 48 hours) permanent pacemaker implantation (PPM) after transcatheter aortic valve implantation (TAVI).

**METHODS** Consecutive patients were identified by retrospective review of a dedicated TAVI database of a single high-volume centre in Milan, Italy between October 2007 and July 2015. Clinical and procedural data were collected to determine predictors of conduction disturbances requiring a PPM at least 48 hours following TAVI.